home / stock / drtsw / drtsw news

DRTSW News and Press, Alpha Tau Medical Ltd. Warrant From 08/28/23

Stock Information
Company Name: Alpha Tau Medical Ltd. Warrant
Stock Symbol: DRTSW
Market: NASDAQ
Website: alphatau.com
Menu
DRTSW DRTSW Quote DRTSW Short DRTSW News DRTSW Articles DRTSW Message Board
Get DRTSW Alerts

News, Short Squeeze, Breakout and More Instantly...
DRTSW - Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR , two-year local recurrence-free survival of 77% , and no treatment-related grade 2 or higher late-onset toxicity ...
DRTSW - Alpha Tau Medical to Participate in September Investor Conferences

JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences. ...

DRTSW - Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year local recurrence-free survival rate of 77%. - The analysis also showed no grade 3 or higher acute treatment-related toxicities, with approx. 2...

DRTSW - Alpha Tau Medical to Participate in June Investor Conferences

JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor con...
DRTSW - Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update

- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer , which began enrolling patient s in March - - Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in A...

DRTSW - Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with squamous cell carcinoma of the vul...

DRTSW - Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or systemic toxicity reported in the 10 patients treated in the feasibility and safety study of intratumoral Alpha DaRT for the treatment of recurrent or unresectable skin ...
DRTSW - Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day

JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will take part in a ...

DRTSW - Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with advanced inoperable pancreatic c...

DRTSW - Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit

JERUSALEM, March 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present in-pe...
Previous 10 Next 10